Payment overview · 2025
General Payments
$166.49
10 reported records · 5 companies
Healthcare provider profile · identity verified
Nancy L Verhoff, MD
Allopathic & Osteopathic Physicians|Family Medicine · WILLARD, OH · NPI 1275535882
Verified facts
What the public records show
CMS Open Payments records show Nancy L Verhoff, MD received $166.49 in general payments during 2025 across 10 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 44.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $73.97 | 44.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.37 | 23.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.34 | 20.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.07 | 8.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4.74 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $166.49 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $73.97 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.37 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.37 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.34 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 555 | 141 |
| Lisinopril | Lisinopril | 495 | 115 |
| Hydrochlorothiazide | Hydrochlorothiazide | 437 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 392 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 356 | 74 |
| Metformin Hcl | Metformin Hcl | 343 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 258 | 60 |
| Simvastatin | Simvastatin | 254 | 61 |
| Omeprazole | Omeprazole | 240 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 51 |
| Losartan Potassium | Losartan Potassium | 195 | 51 |
| Potassium Chloride | Potassium Chloride | 175 | 37 |
| Gabapentin | Gabapentin | 161 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 158 | 36 |
| Montelukast Sodium | Montelukast Sodium | 145 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 124 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 29 |
| Alendronate Sodium | Alendronate Sodium | 117 | 18 |
| Metformin Hcl Er | Metformin Hcl | 117 | 35 |
| Glimepiride | Glimepiride | 116 | 32 |
| Tramadol Hcl | Tramadol Hcl | 116 | 27 |
| Meloxicam | Meloxicam | 106 | 26 |
| Lovastatin | Lovastatin | 101 | 18 |
| Eliquis | Apixaban | 99 | 14 |
| Trazodone Hcl | Trazodone Hcl | 93 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 24 |
| Synthroid | Levothyroxine Sodium | 89 | 20 |
| Furosemide | Furosemide | 87 | 33 |
| Sertraline Hcl | Sertraline Hcl | 87 | 16 |
| Warfarin Sodium | Warfarin Sodium | 81 | 13 |
| Famotidine | Famotidine | 80 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 17 |
| Buspirone Hcl | Buspirone Hcl | 76 | 22 |
| Glipizide | Glipizide | 76 | 13 |
| Atenolol | Atenolol | 74 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 28 |
| Spironolactone | Spironolactone | 71 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 15 |
| Glipizide Er | Glipizide | 67 | 12 |
| Alprazolam | Alprazolam | 66 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 13 |
| Celecoxib | Celecoxib | 61 | 13 |
| Allopurinol | Allopurinol | 60 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 14 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 55 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 25 |
| Carvedilol | Carvedilol | 53 | 13 |
| Jardiance | Empagliflozin | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 11 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Sucralfate | Sucralfate | 48 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 40 |
| Ozempic | Semaglutide | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Glyburide | Glyburide | 42 | suppressed |
| Prednisone | Prednisone | 39 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 14 |
| Cephalexin | Cephalexin | 37 | 27 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Azithromycin | Azithromycin | 30 | 26 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 22 |
| Ramipril | Ramipril | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Metronidazole | Metronidazole | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Mesalamine Dr | Mesalamine | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $166.49 · 10 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, Cologuard Collection Kit, NURTEC ODT, QULIPTA, UBRELVY, VOQUEZNA, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error